DE602004027515D1 - Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz - Google Patents

Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz

Info

Publication number
DE602004027515D1
DE602004027515D1 DE602004027515T DE602004027515T DE602004027515D1 DE 602004027515 D1 DE602004027515 D1 DE 602004027515D1 DE 602004027515 T DE602004027515 T DE 602004027515T DE 602004027515 T DE602004027515 T DE 602004027515T DE 602004027515 D1 DE602004027515 D1 DE 602004027515D1
Authority
DE
Germany
Prior art keywords
megestrol acetate
heart failure
cardiac function
treat heart
improve cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004027515T
Other languages
English (en)
Inventor
Stefan Anker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Par Pharmaceuticals Inc
Original Assignee
Par Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Par Pharmaceuticals Inc filed Critical Par Pharmaceuticals Inc
Publication of DE602004027515D1 publication Critical patent/DE602004027515D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602004027515T 2004-12-01 2004-12-01 Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz Active DE602004027515D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04028474A EP1669074B1 (de) 2004-12-01 2004-12-01 Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz

Publications (1)

Publication Number Publication Date
DE602004027515D1 true DE602004027515D1 (de) 2010-07-15

Family

ID=34927608

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027515T Active DE602004027515D1 (de) 2004-12-01 2004-12-01 Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz

Country Status (9)

Country Link
US (3) US8383612B2 (de)
EP (2) EP1669074B1 (de)
AT (1) ATE469650T1 (de)
DE (1) DE602004027515D1 (de)
DK (1) DK1669074T3 (de)
ES (2) ES2346755T3 (de)
PL (1) PL1863492T3 (de)
SI (1) SI1669074T1 (de)
WO (1) WO2006058748A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005318464B2 (en) 2004-12-23 2012-02-23 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization
WO2009071405A1 (en) * 2007-12-04 2009-06-11 Charité - Universitätsmedizin Berlin Megestrol acetate for reducing the mortality and/or improving quality of life in cancer patients
US10334873B2 (en) 2016-06-16 2019-07-02 Altria Client Services Llc Breakable capsules and methods of forming thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370321A (en) * 1976-09-01 1983-01-25 Mead Johnson And Company Progestational adjuvant therapy
US5144017A (en) * 1988-07-13 1992-09-01 University Of Manitoba Compounds that bind to digitalis receptor
SE9600046D0 (sv) * 1996-01-05 1996-01-05 Astra Ab New pharmaceutical formulation
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
AU2003230885A1 (en) * 2002-04-12 2003-10-27 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
AU2003278434A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins

Also Published As

Publication number Publication date
DK1669074T3 (da) 2010-09-27
US20160101117A1 (en) 2016-04-14
EP1863492A1 (de) 2007-12-12
US20130143848A1 (en) 2013-06-06
SI1669074T1 (sl) 2010-10-29
EP1863492B1 (de) 2013-05-08
ES2423944T3 (es) 2013-09-25
PL1863492T3 (pl) 2013-10-31
EP1669074A1 (de) 2006-06-14
EP1669074B1 (de) 2010-06-02
US8383612B2 (en) 2013-02-26
WO2006058748A1 (en) 2006-06-08
ATE469650T1 (de) 2010-06-15
US20080139521A1 (en) 2008-06-12
ES2346755T3 (es) 2010-10-20

Similar Documents

Publication Publication Date Title
EA200700058A1 (ru) Соединения, композиции и способы их использования
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
MXPA02007639A (es) Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
ATE534747T1 (de) 1l1rl-1 als marker für kardiovaskuläre erkrankungen
ATE521608T1 (de) Glucokinaseaktivatoren
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE539748T1 (de) Glucokinaseaktivatoren
DE60113548D1 (de) Cyanomethyl-substituierte thiazolium- und imidazolium-verbindungen und behandlung von erkrankungen im zusammenhang mit proteinalterung
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
NZ716245A (en) Fused benzoxazepinones as ion channel modulators
ATE400297T1 (de) Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
MX2007007781A (es) Composiciones cardiovasculares.
ATE486595T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur senkung der lipid- und blutzuckerspiegel
ATE359087T1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
DE602005011468D1 (de) Gemeinsame gabe von tigecyclin und digoxin
ATE449600T1 (de) Verwendung von glycerin zur verbesserung der herzfunktion
DE602004027515D1 (de) Verwendung von Megestrolacetat zur Verbesserung der Herzfunktion und zur Behandlung von Herzinsuffizienz
DE602004010691D1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
DE602005013542D1 (de) Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18
TR200401952T4 (tr) Kalp dolaşım hastalıklarının profilaksisi ve tedavisi için hiyaluronidaz'ın kullanımı
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
MX2008009161A (es) Tratamiento de enfermedad cardiovascular en mexicano-americanos, usando nebivolol.
BRPI0509740A (pt) compostos para tratamento das arritmias cardìacas e métodos de uso